Q3 2025 Management View CEO Michael Mahoney reported, “In third quarter '25, total company operational sales grew 19% and organic sales grew 15%, exceeding the high end of our guidance range of 12% to ...

Boston Scientific Corporation BSX is scheduled to report second-quarter 2024 results on Jul 24, before the opening bell. In the last reported quarter, the company’s earnings per share of 56 cents ...

Boston Scientific BSX is slated to report fourth-quarter 2025 results on Feb. 4, before market open. The renowned medical device manufacturer posted earnings per share (EPS) of 75 cents in the last ...

17 deaths and 120 serious injuries have been reported due to complications during Watchman procedures. Boston Scientific warned Watchman customers of a higher risk of complications during procedures ...

The U.S. FDA expanded the approval for use of Boston Scientific Corp.’s Watchman Flx and Watchman Flx Pro left atrial appendage closure (LAAC) devices to include post-ablation patients, bringing good ...

FILE - The Boston Scientific logo is seen at company offices in Fremont, Calif., Feb. 1, 2017. (AP Photo/Marcio Jose Sanchez, File) (Marcio Jose Sanchez, Copyright ...

More special care is needed when using the Watchman access systems used to deliver transcatheter left atrial appendage (LAA) closure devices due to a risk for air embolisms, according to an FDA alert.

Boston Scientific’s BSX robust MedSurg segment, driven by endoscopy, neuromodulation and urology businesses, is poised for further growth in the upcoming quarters. The long-term prospects of the ...

Oct 22 (Reuters) - Boston Scientific (BSX.N), opens new tab raised its annual profit forecast on Wednesday, after beating third-quarter profit estimates on strong demand for its heart devices, sending ...